2 weeks Ago By ABMN Staff
Heartland Bank & Trust Co raised its position in Merck & Co., Inc. ( NYSE:MRK – Free Report ) by 8.
5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,405 shares of the company’s stock after buying an additional 898 shares during the period. Merck & Co.
, Inc. accounts for 0.8% of Heartland Bank & Trust Co’s investment portfolio, making the stock its 20th biggest holding.
Heartland Bank & Trust Co’s holdings in Merck & Co., Inc. were worth $1,412,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Merck & Co., Inc.
by 3.8% during the fourth quarter. Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock valued at $9,331,676,000 after acquiring an additional 3,153,333 shares during the last quarter.
Royal Bank of Canada grew its stake in Merck & Co., Inc. by 12.
8% in the 4th quarter. Royal Bank of Canada now owns 14,972,074 shares of the company’s stock valued at $1,632,255,000 after purchasing an additional 1,696,151 shares during the period. Capital World Investors increased its position in shares of Merck & Co.
, Inc. by 67.6% during the 1st quarter.
Capital World Investors now owns 13,954,017 shares of the company’s stock valued at $1,841,233,000 after purchasing an additional 5,627,923 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of Merck & Co., Inc.
by 1.6% during the 4th quarter. Fisher Asset Management LLC now owns 13,551,242 shares of the company’s stock worth $1,477,357,000 after purchasing an additional 212,852 shares during the period.
Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Merck & Co., Inc. by 2.
2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,050,924 shares of the company’s stock worth $1,313,741,000 after purchasing an additional 253,981 shares during the period. Institutional investors own 76.
07% of the company’s stock. Analyst Ratings Changes A number of research firms recently issued reports on MRK. UBS Group decreased their price objective on shares of Merck & Co.
, Inc. from $148.00 to $142.
00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Bank of America decreased their price target on shares of Merck & Co., Inc.
from $150.00 to $145.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st.
Barclays dropped their price objective on Merck & Co., Inc. from $145.
00 to $142.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.
00 target price on shares of Merck & Co., Inc. in a research report on Monday, September 16th.
Finally, Wolfe Research upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, July 31st.
One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $134.58.
Merck & Co., Inc. Trading Down 0.
1 % Shares of MRK opened at $113.56 on Tuesday. Merck & Co.
, Inc. has a twelve month low of $99.14 and a twelve month high of $134.
63. The stock has a market cap of $287.63 billion, a PE ratio of 126.
18, a P/E/G ratio of 1.60 and a beta of 0.39.
The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.
80. The business’s 50-day moving average price is $116.46 and its 200-day moving average price is $123.
97. Merck & Co., Inc.
( NYSE:MRK – Get Free Report ) last posted its earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $2.
16 by $0.12. Merck & Co.
, Inc. had a net margin of 21.99% and a return on equity of 40.
69%. The business had revenue of $16.10 billion for the quarter, compared to analyst estimates of $15.
87 billion. During the same quarter in the prior year, the firm posted ($2.06) EPS.
Merck & Co., Inc.’s revenue was up 7.
1% on a year-over-year basis. On average, equities analysts forecast that Merck & Co., Inc.
will post 8.01 EPS for the current fiscal year. Merck & Co.
, Inc. Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be issued a $0.
77 dividend. The ex-dividend date is Monday, September 16th. This represents a $3.
08 annualized dividend and a dividend yield of 2.71%. Merck & Co.
, Inc.’s payout ratio is currently 342.22%.
Merck & Co., Inc. Company Profile ( Free Report ) Merck & Co, Inc operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. See Also Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Merck & Co., Inc. ( NYSE:MRK – Free Report ).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co.
Inc. and related companies with MarketBeat.com's FREE daily email newsletter .
.
